All News
Filter News
Found 808,690 articles
-
Embattled SQZ Biotechnologies announced Tuesday that the Swiss biotech will not exercise its option for HPV 16 positive solid tumors under the SQZ-APC-HPV program.
-
The license and option deal, for an undisclosed amount, seeks to develop potentially first-in-class antibody-drug conjugate candidates against different oncology targets.
-
Late-stage data, which showed significant overall and progression-free survival benefits in unresectable hepatocellular carcinoma patients, supports Elevar's New Drug Application filed in May 2023.
-
Following two BLA rejections for its Humira biosimilar, Alvotech is expanding its partnership with Teva Pharmaceuticals, which will enable the latter to have greater involvement with quality and control.
-
IntelGenx Provides Update on Research Collaboration Evaluating Montelukast VersaFilm® for the Treatment of Parkinson’s Disease
7/25/2023
IntelGenx Corp. today announced the execution of a Research Grant Agreement with Karolinska University Hospital and that the manufacturing of both active and placebo films are underway in preparation for a planned multicentre, randomized, double-blind, placebo-controlled clinical study (the “Study”) to investigate the use of IntelGenx’s Montelukast VersaFilm ® for the treatment of Parkinsons Disease.
-
VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients
7/25/2023
Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced the publication of new data demonstrating VitaGraft Kidney’s novel ability to help physicians treat kidney transplant patients more precisely, quickly, and effectively.
-
Illumina and Pillar Biosciences partner to improve access to personalized cancer treatment options
7/25/2023
Illumina Inc. and Pillar Biosciences Inc., the pioneers of Decision Medicine™, today announced a strategic partnership to make Pillar's suite of oncology assays commercially available globally as part of the Illumina portfolio of oncology products.
-
Rosalind Franklin University Researcher Awarded NIH Funding to Investigate Links Between Down Syndrome and Alzheimer's Disease
7/25/2023
NORTH CHICAGO, ILLINOIS, July 25, 2023 — Research scientists at Rosalind Franklin University and New York University are teaming up in an attempt to generate new therapeutic approaches to combat the onset of Alzheimer’s disease (AD) in individuals with Down syndrome (DS), the most common chromosomal disorder and cause of intellectual disability.
-
NeuroOne Medical Technologies Corporation Announces Pricing of Public Offering of Common Stock - July 25, 2023
7/25/2023
NeuroOne Medical Technologies Corporation announced today the pricing of an underwritten registered public offering of 5,250,000 shares of its common stock at a price of $1.00 per share.
-
Fapon Launches the Most Efficient Chemiluminescence Immunoassay Analyzer to Date with Throughput of 900 T/h
7/25/2023
Fapon, a global leading life sciences company, has announced the launch of its latest chemiluminescence immunoassay system Shine i8000/9000 to global markets at the 2023 AACC exhibition.
-
Better Therapeutics Announces $6.7 Million in New Financing at an Average Price of $0.77 per Share
7/25/2023
Better Therapeutics, Inc today announced that it issued 2,023,583 shares of its common stock under its At-The-Market program at an average price per share of $1.19.
-
Adaptive Research Appoints Kristin Andruska, MD, PhD as Senior Medical Director and Clinical Neuroscience & Scientific Research Director
7/25/2023
Adaptive Research, is pleased to announce Kristin Andruska, MD, PhD has been appointed Senior Medical Director of Clinical Neuroscience and Scientific Research Director.
-
Sensus Healthcare Completes Installation of its First SRT System in Ireland
7/25/2023
Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, has installed the first SRT-100™ System in Ireland at Dublin’s Beacon Hospital.
-
Thermo Fisher Relies on CYBRA’s RFID Tracking and Alerting Capabilities to Keep Blood Cold
7/25/2023
CYBRA Corporation, the New York-based developers of Edgefinity IoT® tracking software, announced the release of their latest case study highlighting the strategic value of an RFID-based tracking solution for the health and sciences industry.
-
Stoke Therapeutics Announces Positive New Safety & Efficacy Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) & the SWALLOWTAIL OLE Study in Children & Adolescents with Dravet Syndrome
7/25/2023
Stoke Therapeutics, Inc. announced positive new safety and efficacy data from patients treated with STK-001 in the two ongoing Phase 1/2a studies and the SWALLOWTAIL open-label extension study in children and adolescents with Dravet syndrome.
-
Intrommune Therapeutics Completes Last Patient Last Visit in the Phase 1 OMEGA Study for Peanut Allergy
7/25/2023
Intrommune Therapeutics, Inc. today announced they have achieved Last Patient Last Visit in the Phase 1 OMEGA Clinical Study for patients with peanut allergy.
-
Pliant Therapeutics to Participate in Upcoming Investor Conferences - July 25, 2023
7/25/2023
Pliant Therapeutics, Inc., a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, announced participation in the following August investor conferences.
-
MindBio Therapeutics Begins Recruitment of Participants for World First LSD-Microdosing Clinical Trial in Cancer Patients Experiencing Emotional Distress
7/25/2023
MindBio Therapeutics Corp. is pleased to have started selection of participants for its Phase 2 randomized double-blind and placebo controlled clinical trial in advanced stage cancer patients using microdoses of Lysergic Acid Diethylamide (LSD) and Meaning Centred Psychotherapy in a world's first LSD take-home 6-week trial involving a total of 40 participants.
-
Merck is Safeguarding the Environment Through Green Chemistry
7/25/2023
Many of us are trying to go green, changing our behavior and lifestyles to reduce our impact on the environment.
-
MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts
7/25/2023
MoonLake Immunotherapeutics AG today announced that it has successfully completed randomization of the target 200 patients, several weeks ahead of schedule, in its global Phase 2 ARGO clinical trial evaluating Nanobody® sonelokimab in active psoriatic arthritis (PsA).